Montelukast : more than a cysteinyl leukotriene receptor antagonist?
Loading...
Date
Authors
Tintinger, Gregory Ronald
Feldman, Charles
Theron, Annette J.
Anderson, Ronald
Journal Title
Journal ISSN
Volume Title
Publisher
Hindawi Publishing Corporation
Abstract
The prototype cysteinyl leukotriene receptor antagonist, montelukast, is generally considered to have a niche application in the therapy of exercise- and aspirin-induced asthma. It is also used as add-on therapy in patients whose asthma is poorly controlled with inhaled corticosteroid monotherapy, or with the combination of a long-acting β(2)-agonist and an inhaled corticosteroid. Recently, however, montelukast has been reported to possess secondary anti-inflammatory properties, apparently unrelated to conventional antagonism of cysteinyl leukotriene receptors. These novel activities enable montelukast to target eosinophils, monocytes, and, in particular, the corticosteroid-insensitive neutrophil, suggesting that this agent may have a broader spectrum of anti-inflammatory activities than originally thought. If so, montelukast is potentially useful in the chemotherapy of intermittent asthma, chronic obstructive pulmonary disease, cystic fibrosis, and viral bronchiolitis, which, to a large extent, involve airway epithelial cell/neutrophil interactions. The primary objective of this mini-review is to present evidence for the cysteinyl leukotriene–independent mechanisms of action of montelukast and their potential clinical relevance.
Description
Keywords
Chronic obstructive pulmonary disease, Cyclic AMP, Cysteinyl leukotrienes, Cystic fibrosis, Histone acetyltransferase, 5-lipoxygenase, Cyclic nucleotide phospodiesterase, Sepsis, Viral bronchiolitis
Sustainable Development Goals
Citation
Tintinger, G.R., Feldman, C., Theron, A.J., and Anderson, R. (2010) Montelukast: more than a cysteinyl leukotriene receptor antagonist? TheScientificWorldJOURNAL 10, 2403–2413. DOI 10.1100/tsw.2010.229.